Teva expands API site in Hungary

Teva ($TEVA) is set to start manufacturing activities at a newly expanded facility in Hungary following a HUF 2.3 billion ($8.4 million) project to bolster capacity there, according to local reports.

Teva started on its Sajóbabony site expansion in September, the Budapest Business Journal reported, and production will ramp up this summer. Over the past two decades, Teva has committed HUF 350 billion ($1.3 billion) toward its activities in the country, the BBJ said.

The site at Sajóbabony is one of three in the Eastern European country owned by the Israeli generics giant, with the others at Debrecen and Gödöllő. According to a previous FiercePharmaManufacturing report, Teva produces active pharmaceutical ingredients at Sajóbabony, tablet products at Debrecen and sterile injectable meds at Gödöllő.

In 2012, Teva opened its $110 million Gödöllő plant--which boasts 6 production lines capable of producing 160 million to 200 million units of injectable meds annually--to make meds for more than 70 countries including the U.S., Europe and Far East.

The generics company now employs more than 3,000 people in the country with its operations there dating back to 1993.

Hungarian Prime Minister Viktor Orbán

At the time of the Gödöllő opening, Hungarian Prime Minister Viktor Orbán used the occasion as an opportunity to pledge the government's support to growing the local pharmaceutical sector. Teva, which is working on finishing a $40.5 billion acquisition of Allergan's generics business, isn't alone in producing generics there. Budapest-based Gedeon Richter's operations date back to 1901.

Teva did not respond to a FiercePharmaManufacturing request for further details on the expansion.

- here's the BBJ report

Suggested Articles

WuXi Biologics says it will build a dedicated facility to manufacture a commercial vaccine product for a client in a $3 billion contract.

Catalent's newly acquired Paragon Bioservices will expand its capacity to as much as 425,000 square feet to manufacture therapies for Sarepta.

Paul McKenzie has become COO of CSL Behring, having left Biogen as it struggles following the failure of its late-stage Alzheimer’s candidate.